Skip to NavigationSkip to content

artificial intelligence

Key legal considerations in accelerating pharma using artificial intelligence

Published on 04/09/19 at 12:55pm

Charlotte Walker-Osborn, Partner and International Technology Sector Head and Nabil Asaad, Senior Associate, Intellectual Property Law Group – both from global law firm Eversheds Sutherland – discuss the intricacies of pharma/AI partnerships, including data privacy, cyber security, and intellectual property concerns.

Recent advances in the development of artificial intelligence (AI), coupled with the availability of sufficient computing power to enable their effective use, have now made the application of AI methods to pharmaceutical R&D a realistic prospect.

AI better than radiologists at diagnosing lung cancer

An artificial intelligence (AI) is better than specialist doctors at diagnosing lung cancer, according to a study from researchers at Google and Northwestern University in Illinois.

While not yet ready for clinical use, it is hoped that the technology will boost the effectiveness of cancer screening in the future.

The study, published in the journal Nature Medicine, outlines a deep learning algorithm that is able to predict a patient’s risk of lung cancer.

Kyowa Hakko Kirin signs drug discovery deal with AI firm InveniAI

Japanese pharma and biotech firm Kyowa Hakko Kirin is joining the growing trend of investing in artificial intelligence to bolster drug discovery efforts, entering a new partnership with AI and machine learning firm InveniAI.

KHK hopes to utilise InveniAI’s AlphaMeld technology to discover how its existing pipeline products can be applied to other indications.

While the exact financial details of the deal were not disclosed, it was confirmed that an upfront sum will be paid to InveniAI, as well as a number of development and commercialisation payments.

Robot addresses British MPs over future of AI

British MPs questioned the first robot to ever attend a UK parliamentary meeting this month, after a robot called Pepper offered insight into the future of Artificial Intelligence (AI).

The robot told MPs that “Assistive intelligent robots for older people could relieve pressure on hospitals and care homes as well as improve the care delivery at home and promote independent living for the elderly people.”

Top Ten most popular articles on Pharmafile.com this week

It's top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research conducted at Queen Mary University of London, up to 64% of antiobiotics made and sold in India are unapproved.

Elsewhere, the M&A engine keeps chugging as Allergan snapped up Elastagen and its skincare molecule for $95 million. But the most popular news this week was the blow dealt to Novartis as it learned its generic version to GSK's Advair will be delayed to market.

The future is now: The transformative power of AI

Published on 05/02/18 at 02:26pm

With the technologies reaching exciting levels of maturity and adoption, Matt Fellows investigates how AI and machine learning can be transformative for some of pharma’s age-old problems.

Read Pharmafocus January/February 2018 edition online now!

With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine a more explosive start to the year, as the dust that had settled on a year characterised by stagnation in the mergers & acquisitions department is swiftly blown away with two major deals in one day: Sanofi shells out $11.6 billion for Bioverativ, and Celgene splashes $9 billion to acquire the rest of Juno Therapeutics.

Artificial Intelligence could take over 250,000 UK roles by 2030

Ahead of the government’s expected digital strategy publication tomorrow, a new report has been released looking into how AI could change the face of employment in the UK. According to Think Tank Reform, as many as 250,000 public sector jobs could be performed by AI, through the use of chat bots and drones.

BenevolentAI announces licensing agreement with Janssen

BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, of Johnson & Johnson. BenevolentAI will use their artificial intelligence technology, named the Judgement Augmented Cognition System, to provide their scientists with the tools to analyse vast amounts of scientific data.

What could artificial intelligence mean for pharma?

Published on 15/01/16 at 10:22am
Photo: Shutterstock

With ever rising costs in research and development, the frustratingly long time spent in bringing new novel drugs to market and the high rate of failure in these processes needs to be tackled.

The majority of drugs take a decade or more to come to market, cost billions, and can even ruin a company if they fail in late-stage trials having poured in so much investment.

Step forward Artificial Intelligence (AI); a concept becoming more and more important in addressing these issues and looking increasingly like the future of drug discovery.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches